Search
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.
Products: Nb-atorvastatinLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (
Telotristat ethyl
go.drugbank.com/drugs/DB12095Approved[A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937] … [A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.
Synonyms: 16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dioneCamphor
go.drugbank.com/drugs/DB01744ApprovedInvestigationalWithdrawnThe FDA ruled that camphorated oil could not be marketed in the United States and that no product could contain a concentration higher than 11%.
Mixtures: Zam-Buk Ointment, Delsym No Mess Vapor Roll OnProducts: Just Cbd Roll-ON Warming, Pain Relief Roll-On MuscleOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEthinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnStructurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates … Nevertheless, the medication itself is generally no longer effective after using it for greater than 7 days.
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineTagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigational[A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is